Huntington Disease - Pipeline Review, H1 2017

  • ID: 4311842
  • Drug Pipelines
  • 299 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Evotec AG
  • Ipsen SA
  • NeuroNascent Inc
  • Probiodrug AG
  • SOM Biotech SL
  • MORE
Huntington Disease - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease - Pipeline Review, H1 2017, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.

Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Huntington Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 6, 50 and 18 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 22 and 5 molecules, respectively.

Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Evotec AG
  • Ipsen SA
  • NeuroNascent Inc
  • Probiodrug AG
  • SOM Biotech SL
  • MORE
  1. Introduction
  2. Huntington Disease - Overview
  3. Huntington Disease - Therapeutics Development
  4. Huntington Disease - Therapeutics Assessment
  5. Huntington Disease - Companies Involved in Therapeutics Development
  6. Huntington Disease - Drug Profiles
  7. Huntington Disease - Dormant Projects
  8. Huntington Disease - Discontinued Products
  9. Huntington Disease - Product Development Milestones
  10. Appendix
List of Tables:
  1. Number of Products under Development for Huntington Disease, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Companies, H1 2017 (Contd..1), H1
  4. Number of Products under Development by Companies, H1 2017 (Contd..2), H1
  5. Number of Products under Development by Companies, H1 2017 (Contd..3), H1
  6. Number of Products under Development by Universities/Institutes, H1
  7. Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1
  8. Products under Development by Companies, H1
  9. Products under Development by Companies, H1 2017 (Contd..1), H1
  10. Products under Development by Companies, H1 2017 (Contd..2), H1
  11. Products under Development by Companies, H1 2017 (Contd..3), H1
  12. Products under Development by Companies, H1 2017 (Contd..4), H1
  13. Products under Development by Universities/Institutes, H1
  14. Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1
  15. Number of Products by Stage and Target, H1
  16. Number of Products by Stage and Target, H1 2017 (Contd..1), H1
  17. Number of Products by Stage and Target, H1 2017 (Contd..2), H1
  18. Number of Products by Stage and Mechanism of Action, H1
  19. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1
  20. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1
  21. Number of Products by Stage and Route of Administration, H1
  22. Number of Products by Stage and Molecule Type, H1
  23. Huntington Disease - Pipeline by Addex Therapeutics Ltd, H1
  24. Huntington Disease - Pipeline by AFFiRiS AG, H1
  25. Huntington Disease - Pipeline by Angita BV, H1
  26. Huntington Disease - Pipeline by Annexon Inc, H1
  27. Huntington Disease - Pipeline by Azevan Pharmaceuticals Inc, H1
  28. Huntington Disease - Pipeline by BioCrea GmbH, H1
  29. Huntington Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H1
  30. Huntington Disease - Pipeline by Celon Pharma SA, H1
  31. Huntington Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1
  32. Huntington Disease - Pipeline by Evotec AG, H1
  33. Huntington Disease - Pipeline by Galenea Corp, H1
  34. Huntington Disease - Pipeline by Genervon Biopharmaceuticals LLC, H1
  35. Huntington Disease - Pipeline by Horizon Pharma Plc, H1
  36. Huntington Disease - Pipeline by Immungenetics AG, H1
  37. Huntington Disease - Pipeline by InMed Pharmaceuticals Inc, H1
  38. Huntington Disease - Pipeline by Ionis Pharmaceuticals Inc, H1
  39. Huntington Disease - Pipeline by Ipsen SA, H1
  40. Huntington Disease - Pipeline by Kadmon Corp LLC, H1
  41. Huntington Disease - Pipeline by KineMed Inc, H1
  42. Huntington Disease - Pipeline by Krenitsky Pharmaceuticals Inc, H1
  43. Huntington Disease - Pipeline by Living Cell Technologies Ltd, H1
  44. Huntington Disease - Pipeline by Medesis Pharma SA, H1
  45. Huntington Disease - Pipeline by Mitochon Pharmaceuticals Inc, H1
  46. Huntington Disease - Pipeline by Neuralstem Inc, H1
  47. Huntington Disease - Pipeline by Neurimmune Holding AG, H1
  48. Huntington Disease - Pipeline by Neurocrine Biosciences Inc, H1
  49. Huntington Disease - Pipeline by NeuroNascent Inc, H1
  50. Huntington Disease - Pipeline by New World Laboratories Inc, H1
  51. Huntington Disease - Pipeline by nLife Therapeutics SL, H1
  52. Huntington Disease - Pipeline by Novartis AG, H1
  53. Huntington Disease - Pipeline by NsGene A/S, H1
  54. Huntington Disease - Pipeline by Omeros Corp, H1
  55. Huntington Disease - Pipeline by Oryzon Genomics SA, H1
  56. Huntington Disease - Pipeline by Probiodrug AG, H1
  57. Huntington Disease - Pipeline by ProQR Therapeutics NV, H1
  58. Huntington Disease - Pipeline by PTC Therapeutics Inc, H1
  59. Huntington Disease - Pipeline by QR Pharma Inc, H1
  60. Huntington Disease - Pipeline by reMYND NV, H1
  61. Huntington Disease - Pipeline by Sage Therapeutics Inc, H1
  62. Huntington Disease - Pipeline by Shire Plc, H1
  63. Huntington Disease - Pipeline by SOM Biotech SL, H1
  64. Huntington Disease - Pipeline by Spark Therapeutics Inc, H1
  65. Huntington Disease - Pipeline by Stealth BioTherapeutics Inc, H1
  66. Huntington Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H1
  67. Huntington Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H1
  68. Huntington Disease - Pipeline by Ultragenyx Pharmaceutical Inc, H1
  69. Huntington Disease - Pipeline by UniQure NV, H1
  70. Huntington Disease - Pipeline by Vaccinex Inc, H1
  71. Huntington Disease - Pipeline by Vertex Pharmaceuticals Inc, H1
  72. Huntington Disease - Pipeline by VistaGen Therapeutics Inc, H1
  73. Huntington Disease - Pipeline by Vitality Biopharma Inc, H1
  74. Huntington Disease - Pipeline by VivaCell Biotechnology Espana SL, H1
  75. Huntington Disease - Pipeline by Voyager Therapeutics Inc, H1
  76. Huntington Disease - Pipeline by Vybion Inc, H1
  77. Huntington Disease - Pipeline by WAVE Life Sciences Ltd, H1
  78. Huntington Disease - Pipeline by Wellstat Therapeutics Corp, H1
  79. Huntington Disease - Dormant Projects, H1
  80. Huntington Disease - Dormant Projects, H1 2017 (Contd..1), H1
  81. Huntington Disease - Dormant Projects, H1 2017 (Contd..2), H1
  82. Huntington Disease - Dormant Projects, H1 2017 (Contd..3), H1
  83. Huntington Disease - Dormant Projects, H1 2017 (Contd..4), H1
  84. Huntington Disease - Discontinued Products, H1
List of Figures:
  1. Number of Products under Development for Huntington Disease, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Top 10 Targets, H1
  5. Number of Products by Stage and Top 10 Targets, H1
  6. Number of Products by Top 10 Mechanism of Actions, H1
  7. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  8. Number of Products by Top 10 Routes of Administration, H1
  9. Number of Products by Stage and Top 10 Routes of Administration, H1
  10. Number of Products by Top 10 Molecule Types, H1
  11. Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Addex Therapeutics Ltd
  • AFFiRiS AG
  • Angita BV
  • Annexon Inc
  • Azevan Pharmaceuticals Inc
  • BioCrea GmbH
  • BrainStorm Cell Therapeutics Inc
  • Celon Pharma SA
  • Chong Kun Dang Pharmaceutical Corp
  • Evotec AG
  • Galenea Corp
  • Genervon Biopharmaceuticals LLC
  • Horizon Pharma Plc
  • Immungenetics AG
  • InMed Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Ipsen SA
  • Kadmon Corp LLC
  • KineMed Inc
  • Krenitsky Pharmaceuticals Inc
  • Living Cell Technologies Ltd
  • Medesis Pharma SA
  • Mitochon Pharmaceuticals Inc
  • Neuralstem Inc
  • Neurimmune Holding AG
  • Neurocrine Biosciences Inc
  • NeuroNascent Inc
  • New World Laboratories Inc
  • nLife Therapeutics SL
  • Novartis AG
  • NsGene A/S
  • Omeros Corp
  • Oryzon Genomics SA
  • Probiodrug AG
  • ProQR Therapeutics NV
  • PTC Therapeutics Inc
  • QR Pharma Inc
  • reMYND NV
  • Therapeutics Inc
  • Shire Plc
  • SOM Biotech SL
  • Spark Therapeutics Inc
  • Stealth BioTherapeutics Inc
  • Takeda Pharmaceutical Company Ltd
  • Teva Pharmaceutical Industries Ltd
  • Ultragenyx Pharmaceutical Inc
  • UniQure NV
  • Vaccinex Inc
  • Vertex Pharmaceuticals Inc
  • VistaGen Therapeutics Inc
  • Vitality Biopharma Inc
  • VivaCell Biotechnology Espana SL
  • Vo
  • yager Therapeutics Inc
  • Vybion Inc
  • WAVE Life Sciences Ltd
  • Wellstat Therapeutics Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll